Decoy Therapeutics Inc. (DCOY)
| Market Cap | 2.19M +31.3% |
| Revenue (ttm) | n/a |
| Net Income | -13.03M |
| EPS | -57.12 |
| Shares Out | 531.97K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,247 |
| Open | 3.970 |
| Previous Close | 3.920 |
| Day's Range | 3.850 - 4.120 |
| 52-Week Range | 3.510 - 131.400 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About DCOY
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design α-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting ... [Read more]
Financial Performance
Financial StatementsNews
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus
Decoy Therapeutics (DCOY) announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building ...
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Thera...
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineere...
Decoy Therapeutics registers to sell 3.77M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.77M shares of common stock. The company is not selling any…
Decoy Therapeutics Registration statement: Registration filing
Decoy Therapeutics filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?
Decoy Therapeutics stock rallied on Monday alongside news of new funding for the company.
Decoy Therapeutics Inc trading resumes
09:36 EDT Decoy Therapeutics (DCOY) Inc trading resumes
Decoy Therapeutics Inc trading halted, volatility trading pause
09:31 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of a...
Decoy Therapeutics Registration statement: Registration filing
Decoy Therapeutics filed a registration statement on June 15, 2026, providing details about a securities offering with the SEC.
Decoy Therapeutics files to sell 808,000 shares of common stock for holders
06:13 EDT Decoy Therapeutics (DCOY) files to sell 808,000 shares of common stock for holders
Decoy Therapeutics Inc trading resumes
11:52 EDT Decoy Therapeutics (DCOY) Inc trading resumes
Decoy Therapeutics Inc trading halted, volatility trading pause
11:42 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeut...
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Proxy statement: Proxy filing
Decoy Therapeutics filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic CAMBRIDGE, Mass., June 1,...
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development NEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therap...
Decoy Therapeutics Quarterly report: Q1 2026
Decoy Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley...
Decoy Therapeutics Transcript: Status update
AI-designed multi-antivirals are advancing toward clinical trials, targeting large unmet needs in respiratory infections with rapid, cost-effective development and broad-spectrum efficacy. Strategic partnerships and non-dilutive funding support growth, with significant milestones expected in the next 12–24 months.
Decoy Therapeutics Press release: Status update
Decoy Therapeutics issued a press release on April 9, 2026, disclosing material business information to investors.
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral markets Company to participate in Virtual Investor Closing Bell event to discuss...